Anti-PD-1/L1 antibody plus anti-VEGF antibody <i>vs.</i> plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis.

Explor Target Antitumor Ther · 2024 · PMC11220314 · PMID 38966165

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Similarly, treatment with atezolizumab with cabozantinib in COSMIC-312 significantly improved PFS compared to SOR, but it did not reach statistical significance for OS [ 12 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.